Literature DB >> 27057432

Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2.

Tuanjie Li1, Qi Zhang2, Yuming Jiang1, Jiang Yu1, Yanfeng Hu1, Tingyu Mou1, Guihua Chen3, Guoxin Li1.   

Abstract

Defects in natural killer (NK) cell functions are necessary for tumor immune escape, but their underlying regulatory mechanisms in human cancers remain largely unknown. Here we showed, in detailed studies of NK cells from 235 untreated patients with gastric cancer (GC), the NK cell density in GC tissues could predict improved survival of patients. However, NK cells were significantly decreased in number with advanced-stage GC. A multivariate Cox analysis revealed that the intratumoral NK cell density was an independent prognostic factor for overall survival and disease-free survival in the GC patients. Most of the intratumoral NK cells exhibited a normal phenotype and secreted normal levels of cytokines, but the expression of Ki67 was decreased compared with NK cells from nontumoral regions. Moreover, the levels of intratumoral NK cells were negatively correlated with the intratumoral expression of cyclooxygenase-2. Furthermore, we found that PGE2 derived from GC cells suppressed NK cell proliferation and increased apoptosis in vitro. These data reveal that tumor-derived PGE2 is critical for inducing NK cell dysfunction in GC and demonstrate that an extensive infiltration of NK cells predicts a good prognosis in patients with GC. Our findings suggest that immunosuppressive barriers erected by tumors greatly hamper the antitumor activity of human NK cells, thereby favoring tumor outgrowth and progression.

Entities:  

Keywords:  Cyclooxygenase-2; gastric cancer; natural killer cell; prostaglandin E2

Year:  2015        PMID: 27057432      PMCID: PMC4801461          DOI: 10.1080/2162402X.2015.1069936

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  34 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Natural killers: cataloging immune cells for immunotherapy.

Authors:  Amanda B Keener
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.

Authors:  Tuanjie Li; Yang Yang; Xuefeng Hua; Guoying Wang; Wei Liu; Changchang Jia; Yan Tai; Qi Zhang; Guihua Chen
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

5.  Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

Authors:  Kimmie Ng; Jeffrey A Meyerhardt; Andrew T Chan; Kaori Sato; Jennifer A Chan; Donna Niedzwiecki; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Alan P Venook; Shuji Ogino; Edward L Giovannucci; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2014-11-27       Impact factor: 13.506

Review 6.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 7.  Tumour immunity: effector response to tumour and role of the microenvironment.

Authors:  Alberto Mantovani; Pedro Romero; A Karolina Palucka; Francesco M Marincola
Journal:  Lancet       Date:  2008-02-13       Impact factor: 79.321

8.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.

Authors:  Namita Kundu; Xinrong Ma; Dawn Holt; Olga Goloubeva; Suzanne Ostrand-Rosenberg; Amy M Fulton
Journal:  Breast Cancer Res Treat       Date:  2008-09-16       Impact factor: 4.872

Review 9.  Cancer-related inflammation and treatment effectiveness.

Authors:  Connie I Diakos; Kellie A Charles; Donald C McMillan; Stephen J Clarke
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

10.  Trial watch: Prognostic and predictive value of the immune infiltrate in cancer.

Authors:  Laura Senovilla; Erika Vacchelli; Jerome Galon; Sandy Adjemian; Alexander Eggermont; Wolf Hervé Fridman; Catherine Sautès-Fridman; Yuting Ma; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more
  25 in total

Review 1.  Role of prostanoids in gastrointestinal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

Review 2.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 4.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

5.  Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.

Authors:  Hyungwoo Cho; Min-Hee Ryu; Hyung Eun Lee; Hyung-Don Kim; Yoon-Koo Kang
Journal:  Cancer Immunol Immunother       Date:  2021-08-22       Impact factor: 6.968

6.  Prognostic and Predictive Value of p21-activated Kinase 6 Associated Support Vector Machine Classifier in Gastric Cancer Treated by 5-fluorouracil/Oxaliplatin Chemotherapy.

Authors:  Yuming Jiang; Wei Liu; Tuanjie Li; Yanfeng Hu; Sile Chen; Sujuan Xi; Yajia Wen; Lei Huang; Liying Zhao; Cuicui Xiao; Xiaohui Huang; Zhen Han; Hao Liu; Xiaolong Qi; Yang Yang; Jiang Yu; Shirong Cai; Guoxin Li
Journal:  EBioMedicine       Date:  2017-07-01       Impact factor: 8.143

7.  Prognostic significance of cystatin SN associated nomograms in patients with colorectal cancer.

Authors:  Taiyuan Li; Qiangqiang Xiong; Zhen Zou; Xiong Lei; Qunguang Jiang; Dongning Liu
Journal:  Oncotarget       Date:  2017-12-08

8.  Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis.

Authors:  Wen Jiang; Ke Liu; Qing Guo; Ji Cheng; Liming Shen; Yinghao Cao; Jing Wu; Jianguo Shi; Heng Cao; Bo Liu; Kaixiong Tao; Guobin Wang; Kailin Cai
Journal:  Oncotarget       Date:  2017-05-03

9.  Prognostic Significance of CSN2, CD8, and MMR Status-Associated Nomograms in Patients with Colorectal Cancer.

Authors:  Bing Zhu; Pei Zhang; Mulin Liu; Congqiao Jiang; Hao Liu; Jun Fu
Journal:  Transl Oncol       Date:  2018-07-31       Impact factor: 4.243

10.  Prognostic significance of nomograms integrating IL-37 expression, neutrophil level, and MMR status in patients with colorectal cancer.

Authors:  Bing Zhu; Jie Luo; Yiyao Jiang; Luhua Yu; Mulin Liu; Jun Fu
Journal:  Cancer Med       Date:  2018-07-13       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.